ERBB2 and gastric cancer: Both studies included the enrollment of patients with HER2-negative, CLDN18.2-positive (moderate or strong membrane staining in ≥75% of tumor cells by IHC) advanced gastric cancer receiving first-line chemotherapy [33,34].